<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311375</url>
  </required_header>
  <id_info>
    <org_study_id>87-03-85-7538</org_study_id>
    <nct_id>NCT01311375</nct_id>
  </id_info>
  <brief_title>Omega 3 in Intervention Spinal Cord Injured People</brief_title>
  <official_title>Evaluation of Omega 3 Supplementation on Neurological Recovery , Lipid Profile and Antioxidant Enzymes and Hormones After Chronic Spinal Cord Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of omega 3 fatty acid on neurological
      recovery, lipid profile and Antioxidant system in patients with spinal cord injury. One
      hundred spinal cord injured patients who come to clinic of spinal injury repair research
      center selected. Then the patients will receive two supplements capsules of omega 3 (600 mg)
      in the intervention group and placebo in the control group. Primary outcome measures are
      professionals evaluation of neurological function by using :

        -  ASIA scale for sensory and motor function

        -  FIM scale for Functional potential

        -  FAM

        -  SF_36 for quality of life

      Lipid profile and Antioxidant profile evaluation by using:

        -  FBS

        -  2hpp

        -  Insulin

        -  LDL

        -  Total cHOL

        -  TG

        -  HDL

        -  Leptin Adiponectin -Calcium-

        -  25OHD

        -  PTH,LH, FSH, Prolactin,Testosterone in males Bone markers by serum levels of
           :Osteocalcin-Osteoprotegrin_Bone Specified ALP- CTX - RANKL

        -  BMD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All no neurological evaluation will be done by experiment researcher under considering of a
      neurologist.All Sub clinical evaluation will be done by specific, sensitive and valid
      laboratory methods. Intervention time will be 14 months.Comparison of these variables will be
      done before and after intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological recovery,metabolic profile and Antioxidant profile evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Primary outcome measures are professionals evaluation of neurological function by using :
Osteocalcin
osteoprotegrin
Bone Specified ALP
CTX
RANKL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological recovery,metabolic profile and Antioxidant profile evaluation in SCI patients</measure>
    <time_frame>14 months</time_frame>
    <description>ASIA scale for sensory and motor function FIM scale for Functional potential FAM
SF36 for quality of life by using:
FBS 2hpp Insulin LDL Total cHOL TG HDL Leptin Adiponectin -Calcium- 25OHD PTH,LH, FSH, Prolactin,Testosterone in males</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological recovery,metabolic profile and Antioxidant profile evaluation in patients with SCI</measure>
    <time_frame>14 months</time_frame>
    <description>BMD : Femur and Lumbar</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Lipid Metabolism Disorders</condition>
  <condition>Peroxidase; Defect</condition>
  <arm_group>
    <arm_group_label>w3 supplement + capsule CA-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+ CA-D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo in the same color,shape,size</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>w3 supplement in SCI</intervention_name>
    <description>supplements(Mor DHA and Ca &quot;500 mg&quot; -D200 micro g&quot; )( will be given in this group</description>
    <arm_group_label>w3 supplement + capsule CA-D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo+ capsule CA-D</description>
    <arm_group_label>placebo+ CA-D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: no metabolic, malignant or kidney disorder, normal TSH, LH, FSH,
        prolactin, and testosterone in men and normal prolactin, estradiol, LH, FSH, and TSH in
        women

        Exclusion Criteria:

          -  pregnancy, lactation, presence of bone disease,hypersensitivity to fish or fish oil,
             hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abbas Nouroozi, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Brain and Spinal Cord Injury Repair Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain and Spinal Injury Repair Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal,, bone, cord injury, lipid,antioxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

